Blood Tests and Risk Factors

After lymphoma returned in his brain, one cancer survivor reflects on hospice, mortality, family, jealousy and gratitude for the life he was able to live.

See how FDA-approved lymphoma treatments have changed over 5 years — what's new, who it's helped, and what's still to come.

Kazia Therapeutics CEO Dr. John Friend discussed how paxalisib is being studied in HR-positive, HER2-negative breast cancer, why researchers are focusing on treatment resistance and what the ongoing clinical trial could show for patients.

An expert discusses August's FDA approvals for myeloma, polycythemia vera and essential thrombocythemia, plus first-line myeloma care and MRD testing.

Patients with colorectal cancer who walked more had less fatigue and better quality of life, regardless of how active they were at diagnosis.

CURE spoke with Oncology Aesthetics & Wellness founder, Deborah A. McDowell, about hair preservation before, during and after cancer treatment.

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

A wife reflects on her husband’s cancer treatment, finding comfort, hope and connection in their simple ritual of sharing bagels before each treatment.